Caribou Biosciences (NASDAQ:CRBU) and SOPHiA GENETICS (NASDAQ:SOPH) Critical Survey

SOPHiA GENETICS (NASDAQ:SOPH) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares SOPHiA GENETICS and Caribou Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$62.37 million	3.86	-$78.98 million	($1.09)	-3.38
Caribou Biosciences	$34.48 million	3.31	-$102.07 million	($1.65)	-0.76

SOPHiA GENETICS has higher revenue and earnings than Caribou Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

SOPHiA GENETICS has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for SOPHiA GENETICS and Caribou Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	0	1	4	0	2.80
Caribou Biosciences	0	0	5	0	3.00

SOPHiA GENETICS currently has a consensus price target of $7.40, suggesting a potential upside of 101.09%. Caribou Biosciences has a consensus price target of $10.33, suggesting a potential upside of 720.11%. Given Caribou Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than SOPHiA GENETICS.

Profitability

This table compares SOPHiA GENETICS and Caribou Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-110.71%	-55.06%	-38.33%
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%

Insider and Institutional Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Caribou Biosciences beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.